Proactiveinvestors Australia Kazia Therapeutics Ltd https://www.proactiveinvestors.com.au Proactiveinvestors Australia Kazia Therapeutics Ltd RSS feed en Fri, 18 Oct 2019 01:04:05 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference https://www.proactiveinvestors.com.au/companies/news/903836/kazia-therapeutics-presents-new-data-from-cantrixil-phase-1-study-in-ovarian-cancer-at-global-conference-903836.html Tue, 01 Oct 2019 02:59:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903836/kazia-therapeutics-presents-new-data-from-cantrixil-phase-1-study-in-ovarian-cancer-at-global-conference-903836.html Kazia Therapeutics presents ovarian cancer study at conference https://www.proactiveinvestors.com.au/companies/news/903700/kazia-therapeutics-presents-ovarian-cancer-study-at-conference-903700.html Mon, 30 Sep 2019 01:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903700/kazia-therapeutics-presents-ovarian-cancer-study-at-conference-903700.html Kazia Therapeutics to share pipeline results with market and clinicians https://www.proactiveinvestors.com.au/companies/news/903409/kazia-therapeutics-to-share-pipeline-results-with-market-and-clinicians-903409.html Wed, 25 Sep 2019 22:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903409/kazia-therapeutics-to-share-pipeline-results-with-market-and-clinicians-903409.html Kazia Therapeutics to present on phase II study of GDC-0084 in glioblastoma at Neuro Oncology meeting in France https://www.proactiveinvestors.com.au/companies/news/903105/kazia-therapeutics-to-present-on-phase-ii-study-of-gdc-0084-in-glioblastoma-at-neuro-oncology-meeting-in-france-903105.html Fri, 20 Sep 2019 02:12:00 +1000 https://www.proactiveinvestors.com.au/companies/news/903105/kazia-therapeutics-to-present-on-phase-ii-study-of-gdc-0084-in-glioblastoma-at-neuro-oncology-meeting-in-france-903105.html Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award https://www.proactiveinvestors.com.au/companies/news/902639/kazia-therapeutics-wins-anzlf-trans-tasman-innovation-and-growth-award-902639.html Fri, 13 Sep 2019 00:48:00 +1000 https://www.proactiveinvestors.com.au/companies/news/902639/kazia-therapeutics-wins-anzlf-trans-tasman-innovation-and-growth-award-902639.html Kazia Therapeutics confirms successful completion of phase I study of its childhood cancer drug https://www.proactiveinvestors.com.au/companies/news/902547/kazia-therapeutics-confirms-successful-completion-of-phase-i-study-of-its-childhood-cancer-drug-902547.html Thu, 12 Sep 2019 04:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/902547/kazia-therapeutics-confirms-successful-completion-of-phase-i-study-of-its-childhood-cancer-drug-902547.html Kazia Therapeutics' cancer drug trials lift valuation to $137 million or $2.20 a share, according to Edison https://www.proactiveinvestors.com.au/companies/news/902275/kazia-therapeutics--cancer-drug-trials-lift-valuation-to-137-million-or-220-a-share-according-to-edison-902275.html Mon, 09 Sep 2019 07:01:00 +1000 https://www.proactiveinvestors.com.au/companies/news/902275/kazia-therapeutics--cancer-drug-trials-lift-valuation-to-137-million-or-220-a-share-according-to-edison-902275.html Kazia Therapeutics a top-10 finalist in ANZLF Trans-Tasman Innovation and Growth Awards https://www.proactiveinvestors.com.au/companies/news/902186/kazia-therapeutics-a-top-10-finalist-in-anzlf-trans-tasman-innovation-and-growth-awards-902186.html Fri, 06 Sep 2019 04:50:00 +1000 https://www.proactiveinvestors.com.au/companies/news/902186/kazia-therapeutics-a-top-10-finalist-in-anzlf-trans-tasman-innovation-and-growth-awards-902186.html Kazia Therapeutics continues to progress clinical assets into FY2020 https://www.proactiveinvestors.com.au/companies/news/901682/kazia-therapeutics-continues-to-progress-clinical-assets-into-fy2020-901682.html Thu, 29 Aug 2019 06:21:00 +1000 https://www.proactiveinvestors.com.au/companies/news/901682/kazia-therapeutics-continues-to-progress-clinical-assets-into-fy2020-901682.html Kazia Therapeutics designated name for brain cancer drug by World Health Organisation https://www.proactiveinvestors.com.au/companies/news/901362/kazia-therapeutics-designated-name-for-brain-cancer-drug-by-world-health-organisation-901362.html Fri, 23 Aug 2019 00:17:00 +1000 https://www.proactiveinvestors.com.au/companies/news/901362/kazia-therapeutics-designated-name-for-brain-cancer-drug-by-world-health-organisation-901362.html Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study https://www.proactiveinvestors.com.au/companies/news/900577/kazia-therapeutics-concludes-recruitment-into-part-b-of-its-phase-i-ovarian-cancer-clinical-study-900577.html Tue, 13 Aug 2019 01:19:00 +1000 https://www.proactiveinvestors.com.au/companies/news/900577/kazia-therapeutics-concludes-recruitment-into-part-b-of-its-phase-i-ovarian-cancer-clinical-study-900577.html Kazia Therapeutics to begin phase I clinical trial for cancer that has spread to the brain https://www.proactiveinvestors.com.au/companies/news/224237/kazia-therapeutics-to-begin-phase-i-clinical-trial-for-cancer-that-has-spread-to-the-brain-224237.html Mon, 22 Jul 2019 01:29:00 +1000 https://www.proactiveinvestors.com.au/companies/news/224237/kazia-therapeutics-to-begin-phase-i-clinical-trial-for-cancer-that-has-spread-to-the-brain-224237.html Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52% https://www.proactiveinvestors.com.au/companies/news/223644/kazia-therapeutics-substantial-holder-willoughby-capital-increases-interest-to-1752-223644.html Wed, 10 Jul 2019 06:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223644/kazia-therapeutics-substantial-holder-willoughby-capital-increases-interest-to-1752-223644.html Kazia Therapeutics substantial shareholder lifts interest to 17.4% https://www.proactiveinvestors.com.au/companies/news/223348/kazia-therapeutics-substantial-shareholder-lifts-interest-to-174-223348.html Thu, 04 Jul 2019 08:13:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223348/kazia-therapeutics-substantial-shareholder-lifts-interest-to-174-223348.html Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research https://www.proactiveinvestors.com.au/companies/news/223001/kazia-therapeutics-has-two-novel-classes-of-anti-cancer-drugs-edison-investment-research-223001.html Fri, 28 Jun 2019 02:34:00 +1000 https://www.proactiveinvestors.com.au/companies/news/223001/kazia-therapeutics-has-two-novel-classes-of-anti-cancer-drugs-edison-investment-research-223001.html Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment https://www.proactiveinvestors.com.au/companies/news/220551/kazia-therapeutics-to-collaborate-with-us-based-oncology-foundation-on-clinical-trials-for-metastatic-brain-cancer-treatment-220551.html Mon, 20 May 2019 02:46:00 +1000 https://www.proactiveinvestors.com.au/companies/news/220551/kazia-therapeutics-to-collaborate-with-us-based-oncology-foundation-on-clinical-trials-for-metastatic-brain-cancer-treatment-220551.html Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon https://www.proactiveinvestors.com.au/companies/news/219839/kazia-therapeutics-gains-new-substantial-holder-in-the-bank-of-new-york-mellon-219839.html Wed, 08 May 2019 04:56:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219839/kazia-therapeutics-gains-new-substantial-holder-in-the-bank-of-new-york-mellon-219839.html Kazia Therapeutics releases new safety data to assist in brain cancer treatments https://www.proactiveinvestors.com.au/companies/news/313249/kazia-therapeutics-releases-new-safety-data-to-assist-in-brain-cancer-treatments-13249.html Wed, 08 May 2019 01:02:00 +1000 https://www.proactiveinvestors.com.au/companies/news/313249/kazia-therapeutics-releases-new-safety-data-to-assist-in-brain-cancer-treatments-13249.html Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients https://www.proactiveinvestors.com.au/companies/news/219706/kazia-therapeutics--ongoing-study-confirms-higher-drug-tolerability-in-newly-diagnosed-glioblastoma-patients-219706.html Mon, 06 May 2019 04:42:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219706/kazia-therapeutics--ongoing-study-confirms-higher-drug-tolerability-in-newly-diagnosed-glioblastoma-patients-219706.html Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours https://www.proactiveinvestors.com.au/companies/news/219425/kazia-therapeutics-studies-evaluate-therapeutic-candidates-in-ovarian-cancer-and-brain-tumours-219425.html Wed, 01 May 2019 22:30:00 +1000 https://www.proactiveinvestors.com.au/companies/news/219425/kazia-therapeutics-studies-evaluate-therapeutic-candidates-in-ovarian-cancer-and-brain-tumours-219425.html Kazia Therapeutics to present positive ovarian cancer drug data at AACR annual meeting https://www.proactiveinvestors.com.au/companies/news/312814/kazia-therapeutics-to-present-positive-ovarian-cancer-drug-data-at-aacr-annual-meeting-12814.html Tue, 02 Apr 2019 02:45:00 +1100 https://www.proactiveinvestors.com.au/companies/news/312814/kazia-therapeutics-to-present-positive-ovarian-cancer-drug-data-at-aacr-annual-meeting-12814.html Kazia Therapeutics will outline anti-cancer drug development strategy at CEO Sessions https://www.proactiveinvestors.com.au/companies/news/214129/kazia-therapeutics-will-outline-anti-cancer-drug-development-strategy-at-ceo-sessions-214129.html Thu, 07 Feb 2019 00:35:00 +1100 https://www.proactiveinvestors.com.au/companies/news/214129/kazia-therapeutics-will-outline-anti-cancer-drug-development-strategy-at-ceo-sessions-214129.html Kazia Therapeutics developing unique drug to battle brain cancer https://www.proactiveinvestors.com.au/companies/news/311805/kazia-therapeutics-developing-unique-drug-to-battle-brain-cancer-11805.html Fri, 11 Jan 2019 15:17:00 +1100 https://www.proactiveinvestors.com.au/companies/news/311805/kazia-therapeutics-developing-unique-drug-to-battle-brain-cancer-11805.html Kazia Therapeutics progresses phase II clinical trial for brain cancer drug https://www.proactiveinvestors.com.au/companies/news/193977/kazia-therapeutics-progresses-phase-ii-clinical-trial-for-brain-cancer-drug-193977.html Wed, 28 Mar 2018 21:28:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193977/kazia-therapeutics-progresses-phase-ii-clinical-trial-for-brain-cancer-drug-193977.html